Predictive Insights.
Personalized Care.
The Patient-Centric eClinical Trials Management Platform
Enhancing Drug Development
AiCure's solutions will help ensure clinical trials achieve statistical power and capture clinically meaningful, objective data.
Gain advantages in drug development with:
AiCure Patient Connect - Improved medication adherence rates and patient engagement
AiCure Platform - More power to analyze and predict treatment response using digital biomarkers
AiCure Site Services - Reduced clinical tech burden so site personnel can increase focus on patients
OpenDBM
Transparent collaborations with industry and academia to sharpen insights into disease progression and patient behavior.
OpenDBM is an open-source platform for the scientific community to access AiCure’s digital biomarker algorithms and apply them to their own data sets to measure patient behavior, encouraging research collaboration to drive innovation and improve understanding of disease symptomatology.
Flexibility To Support Decentralized Trials and Traditional Site-based Trials
Data collected using AiCure’s secure, patient-facing application can support safety and efficacy endpoints and provide a comprehensive view of how therapy impacts patients. AiCure supports the entire spectrum of trials, from traditional site-based trials to site-less, decentralized or virtual trials.
Featured Resources
Curious about improving medication adherence or deploying digital biomarkers? Our featured resources describe the latest innovation in these areas. Learn how life science companies are transforming drug development with AiCure.
Testimonials
AiCure customers are dedicated to elevating clinical research. We are grateful for their support and recognition.
"Having worked with AiCure, they are probably the most advanced in facial recognition and mapping software and the algorithms underlying that to detect subtle clinical changes.”
Matthew Leoni, MD MBA, VP, Global Clinical Development at Cerevel Therapeutics
“The thing I’ve been focusing on is really using AiCure for, rather than a passive data collection tool, is to drive action.”
Sarah Titus, Director of Clinical Operations & Development at Sage Therapeutics
"We did see drop-out rates fall considerably and cut down by more than half. That for us is a big win."
Kyle Holen, MD, Head of Development Design Center at Abbvie